← All trials
NCT05288543
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 11, 2022
- Primary completion
- Oct 30, 2022
- Completion date
- Nov 30, 2022
- First posted
- Mar 21, 2022
- Last posted
- Apr 7, 2022
- Enrollment
- 86
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Nanjing Immunophage Biotech Co., LtdLead sponsor
- NovotechCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.